Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm,...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of ONCO.ST is 2.8 and suggests 67% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell